Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles

被引:40
作者
Dewailly, D. [1 ]
Alebic, M. S. [2 ]
Duhamel, A. [3 ]
Stojanovic, N. [4 ]
机构
[1] CHRU Lille, Hop Jeane de Flandre, Serv Gynecol Endocrinienne & Med Reprod, F-59037 Lille, France
[2] Merkur Univ Hosp, Dept Human Reprod, Zagreb 10000, Croatia
[3] Univ Lille Nord France, Unite Biostat, EA2694, Lille, France
[4] Merkur Univ Hosp, Dept Med Biochem & Lab Med, Zagreb 10000, Croatia
关键词
anti-Mullerian hormone; polycystic ovarian morphology; ovarian follicle; polycystic ovary syndrome; ultrasonography; ANTI-MULLERIAN HORMONE; DIAGNOSTIC-CRITERIA; SYNDROME PCOS; ULTRASOUND; ROTTERDAM; CONSENSUS; DEFINITIONS; PREVALENCE; MEDICINE; EXCESS;
D O I
10.1093/humrep/deu242
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Can cluster analysis can be used to identify a homogeneous subpopulation of women with polycystic ovarian morphology (PCOM) within a very large population of control women in a non-subjective way? Identification and exclusion of the cluster corresponding to women with PCOM from controls improved the diagnostic power of serum anti-Mullerian hormone (AMH) level and follicle number per ovary (FNPO) in discriminating between women with or without polycystic ovary syndrome (PCOS). There is disagreement as to whether women with PCOM should be excluded from the control population when establishing FNPO and AMH diagnostic thresholds for the definition of PCOS and how to identify such women. It has been demonstrated that cluster analysis can detect women with PCOM within the control population through a set of classifying variables among which the most relevant was AMH. The adequacy of this approach has not been confirmed in other clinical settings. This was a retrospective study using clinical and laboratory data derived from the computerized database. The data were collected from March 2011 to May 2013. The study included 893 patients referred for routine infertility evaluation and treatment. The patients were divided into three groups: (i) the control group (n = 621) included women with regular menstrual cycles and no signs of hyperandrogenism (HA), (ii) the full-blown PCOS group (n = 95) consisted of women who were diagnosed as having PCOS based on the presence of both HA and oligo/amenorrhoea (OA), (iii) the mild PCOS group included women with only two items of the Rotterdam classification, i.e. PCOM at ultrasonography according to the FNPO threshold of 12 or more and either OA (n = 110) or HA (n = 67). After exclusion of women with PCOM from the controls, the AMH threshold of 28 pmol/l with specificity 97.5% and sensitivity 84.2% [area under the curve (AUC) 0.948 (95% confidence interval (CI) 0.915-0.982)] and FNPO threshold of 12 with specificity 92.5% and sensitivity 83.2% [AUC 0.940 (95% CI 0.909-0.971)] for identifying PCOS were derived from the receiver operating characteristic curve analysis. The AMH threshold of 28 pmol/l had the same specificity for discriminating the mild and the full-blown PCOS phenotypes from controls. There was no selection bias other than being evaluated for infertility treatment, however, this could also be considered as a limitation of the study as these women may not necessarily be a representative sample of the general population. The study demonstrated that serum AMH has intrinsically a very high potency to detect women with PCOM within a control group. However, the AMH threshold is specific for this method and clinical setting. AMH threshold value for the definition of PCOM is method specific and cannot be universally applied. This study confirmed the results of previous studies that cluster analysis can identify women with PCOM within the very large control population without using a predefined diagnostic threshold for FNPO, and that AMH can detect women with PCOM with a high specificity. The exclusion of PCOM women from the controls by using a cluster analysis should be considered when establishing reference intervals and decision threshold values for various parameters used to characterize PCOS. The authors have no funding/competing interest(s) to declare.
引用
收藏
页码:2536 / 2543
页数:8
相关论文
共 29 条
[1]  
[Anonymous], 2012, EV BAS METH WORKSH P
[2]   Ultrasound assessment of the polycystic ovary: international consensus definitions [J].
Balen, AH ;
Laven, JSE ;
Tan, SL ;
Dewailly, D .
HUMAN REPRODUCTION UPDATE, 2003, 9 (06) :505-514
[3]   Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? [J].
Catteau-Jonard, S. ;
Bancquart, J. ;
Poncelet, E. ;
Lefebvre-Maunoury, C. ;
Robin, G. ;
Dewailly, D. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2012, 40 (02) :223-229
[4]  
Clinical and Laboratory Standards Institute (CLSI), 2005, EP15A2 CLSI, V25
[5]   RANK TRANSFORMATIONS AS A BRIDGE BETWEEN PARAMETRIC AND NONPARAMETRIC STATISTICS [J].
CONOVER, WJ ;
IMAN, RL .
AMERICAN STATISTICIAN, 1981, 35 (03) :124-129
[6]   Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries [J].
Dewailly, D. ;
Gronier, H. ;
Poncelet, E. ;
Robin, G. ;
Leroy, M. ;
Pigny, P. ;
Duhamel, A. ;
Catteau-Jonard, S. .
HUMAN REPRODUCTION, 2011, 26 (11) :3123-3129
[7]   Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society [J].
Dewailly, Didier ;
Lujan, Marla E. ;
Carmina, Enrico ;
Cedars, Marcelle I. ;
Laven, Joop ;
Norman, Robert J. ;
Escobar-Morreale, Hector F. .
HUMAN REPRODUCTION UPDATE, 2014, 20 (03) :334-352
[8]   Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism [J].
Dewailly, Didier ;
Pigny, Pascal ;
Soudan, Benoit ;
Catteau-Jonard, Sophie ;
Decanter, Christine ;
Poncelet, Edouard ;
Duhamel, Alain .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (09) :4399-4405
[9]  
Duijkers IJM, 2010, GYNECOL ENDOCRINOL, V26, P152, DOI [10.3109/09513590903247824, 10.1080/09513590903247824]
[10]   Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? [J].
Eilertsen, Tina B. ;
Vanky, Eszter ;
Carlsen, Sven M. .
HUMAN REPRODUCTION, 2012, 27 (08) :2494-2502